Dec 19 (Reuters) - The U.S. Food and Drug Administration said on Friday it has authorized the marketing of six Altria-owned on! PLUS nicotine pouch products, through a pilot program aimed to fast-track reviews of such products.
The authorization was the first under the pilot program that the FDA launched in September, and applies to six on! PLUS nicotine pouches, which are manufactured by Helix Innovations LLC, an Altria joint venture for the global on! PLUS nicotine pouch portfolio.
The company had applied for premarket authorization for the products in June 2024.
The decision allows the mint, tobacco and wintergreen-flavored pouches, offered in 6 mg and 9 mg nicotine strengths, to be legally sold to adults in the United States.
The FDA said its decision was based on evidence that the products contain lower levels of harmful chemicals, posing a lower risk of cancer and other serious health conditions compared to other smokeless tobacco products. The authorization applies only to the specified products and not to other Helix offerings.
Nicotine pouches, which users insert under the lip, are the fastest-growing category of tobacco products in the U.S., and are generally considered among the lowest-risk smoking alternatives given they do not involve inhalation and do not contain tobacco.
Earlier this year, 20 Zyn products, owned by Philip Morris became the first in the nicotine pouch category to receive market authorization from the FDA in the U.S.
Zyn products were approved in January, more than five years after the company first submitted its application.
Tobacco companies have invested heavily in developing and marketing alternatives to cigarettes as demand for these products grows.
"on! PLUS will resume taking new orders for retail accounts in Florida, North Carolina and Texas and on e-commerce soon," Altria said to Reuters.
Nicotine in adolescence can harm the parts of the brain that control attention, learning, mood and impulse control, according to the U.S. Centers for Disease Control and Prevention.
(Reporting by Sanskriti Shekhar and Juveria Tabassum in Bengaluru; Editing by Alan Barona)
latest_posts
- 1
Nine in 10 German industrial firms expect Iran war to hit business - 2Teen drug use remains low, but survey finds small rise in heroin and cocaine use
- 3'All's Fair,' Ryan Murphy's new show starring Kim Kardashian, hit with scathing reviews: 'A girlboss fever dream'
- 4Finding the Force of Mentorship: Self-awareness Through Direction
- 5Historical mysteries solved by science in 2025
- Mystery foot suggests a second early human relative lived alongside Lucy
- NASA’s history-making moon mission aims to send the first woman and person of color to deep space
- Rights groups condemn Israel Police decision to ban Sudan Genocide protests nationwide
- Vote In favor of Your Favored Language Learning Applications
- From Iran to Israel: An Iranian volunteer’s unlikely stand in wartime
- Aspirin can prevent a serious pregnancy complication — but too few women get it, new report suggests
- NASA's make-or-break moon shot
- 10 Moving Design Frill for Summer 2023
- 'Supergirl' drops 1st teaser trailer: Watch Milly Alcock as Kara Zor-El and the return of Krypto the Superdog
